Table 2. Analysis of overall survival.
| Variable | Group | N | d.f. | P-value | Hazard ratio | Lower 95% confidence interval | Upper 95% confidence interval |
|---|---|---|---|---|---|---|---|
| Univariate analysis | |||||||
| c-Cbl staining intensity | 1 | 32 | 1 | 1 | |||
| 2 | 44 | 1 | 0.1049 | 1.7123 | 0.8939 | 3.2802 | |
| 3 | 25 | 1 | 0.0017 | 3.2627 | 1.5569 | 6.8375 | |
| c-Cbl staining intensity | Continuous | 101 | 1 | 0.0019 | 1.8090 | 1.2448 | 2.6290 |
| Age | Continuous | 101 | 1 | 0.0002 | 1.0664 | 1.0304 | 1.1037 |
| PSA | Continuous | 41 | 1 | 0.0009 | 1.0044 | 1.0018 | 1.0070 |
| Gleason score | Continuous | 100 | 1 | 0.0000 | 1.3670 | 1.2048 | 1.5510 |
| Gleason score | Gleason<7 | 60 | 1 | 1 | |||
| Gleason⩾7 | 40 | 1 | 0.0000 | 4.1135 | 2.3917 | 7.0748 | |
| AJCC stage | 1 | 2 | 1 | 0.2349 | 3.5565 | 0.4384 | 28.8493 |
| 2 | 36 | 1 | 1 | ||||
| 3 | 24 | 1 | 0.0067 | 3.2883 | 1.3912 | 7.7726 | |
| 4 M0 | 16 | 1 | 0.0005 | 4.7513 | 1.9644 | 11.4919 | |
| 4 M1 | 23 | 1 | 0.0000 | 9.0662 | 3.9812 | 20.6460 | |
| Multivariate analysis | |||||||
| c-Cbl staining intensity | Continuous | 100 | 1 | 0.0005 | 1.9895 | 1.3513 | 2.9291 |
| Gleason score | Gleason<7 | 60 | 1 | ||||
| Gleason⩾7 | 40 | 1 | 0.0001 | 3.5851 | 1.9242 | 6.6795 | |
| AJCC stage | 1 | 2 | 1 | 0.1715 | 4.3962 | 0.5265 | 36.7064 |
| 2 | 36 | 1 | |||||
| 3 | 23 | 1 | 0.4293 | 1.4602 | 0.5711 | 3.7333 | |
| 4 M0 | 16 | 1 | 0.0039 | 3.7042 | 1.5206 | 9.0236 | |
| 4 M1 | 23 | 1 | 0.0000 | 8.6743 | 3.6294 | 20.7316 | |
| Variables not in the model | |||||||
| Age | Continuous | 100 | 1 | 0.3219 | |||
| Univariate analysis | |||||||
| TEAD1 staining intensity | 0 | 7 | 1 | 1 | |||
| 1 | 30 | 1 | 0.2966 | 1.9435 | 0.5580 | 6.7693 | |
| 2 | 49 | 1 | 0.1981 | 2.1990 | 0.6624 | 7.3009 | |
| 3 | 10 | 1 | 0.0033 | 7.4536 | 1.9482 | 28.5157 | |
| TEAD1 staining intensity | Continuous | 96 | 1 | 0.0065 | 1.7102 | 1.1621 | 2.5169 |
| Age | Continuous | 96 | 1 | 0.0004 | 1.0673 | 1.0293 | 1.1066 |
| PSA | Continuous | 38 | 1 | 0.0045 | 1.0048 | 1.0015 | 1.0081 |
| Gleason score | Continuous | 94 | 1 | 0.0000 | 1.3415 | 1.1784 | 1.5272 |
| Gleason score | Gleason<7 | 57 | 1 | 1 | |||
| Gleason⩾7 | 37 | 1 | 0.0000 | 4.2115 | 2.3747 | 7.4688 | |
| AJCC stage | 1 | 2 | 1 | 0.1672 | 4.4911 | 0.5331 | 37.8367 |
| 2 | 34 | 1 | 1 | ||||
| 3 | 24 | 1 | 0.0022 | 4.4203 | 1.7105 | 11.4227 | |
| 4 M0 | 16 | 1 | 0.0005 | 5.7426 | 2.1493 | 15.3436 | |
| 4 M1 | 20 | 1 | 0.0000 | 12.0225 | 4.7692 | 30.3073 | |
| Multivariate analysis | |||||||
| TEAD1 staining intensity | Continuous | 94 | 1 | 0.0365 | 1.5615 | 1.0284 | 2.3708 |
| Gleason score | Gleason<7 | 57 | 1 | 1 | |||
| Gleason⩾7 | 37 | 1 | 0.0011 | 3.0741 | 1.5632 | 6.0455 | |
| AJCC stage | 1 | 2 | 1 | 0.0536 | 8.5127 | 0.9677 | 74.8866 |
| 2 | 34 | 1 | 1 | ||||
| 3 | 23 | 1 | 0.0840 | 2.4744 | 0.8855 | 6.9144 | |
| 4 M0 | 16 | 1 | 0.0035 | 4.4048 | 1.6275 | 11.9214 | |
| 4 M1 | 19 | 1 | 0.0000 | 12.6098 | 4.7733 | 33.3118 | |
| Variables not in the model | |||||||
| Age | Continuous | 94 | 1 | 0.0646 | |||
PSA=prostate-specific antigen.
Statistical tests were performed as described in Materials and Methods. For statistical analysis, the AJCC stage 4 tumours were divided into categories without (M0) or with (M1) distant metastases.